Hepatocellular Carcinoma
Conditions
Interventions
Nivolumab is administered intravenously
Sponsors
Kindai University Faculty of Medicine Department of Gastroenterology and Hepatology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Initially diagnosed hepatocellular carcinoma with histological or radiological confirmation. 2.Intermediate or High Risk of recurrence as assessed by tumor characteristics. 3.Child-Pugh A 4.ECOG Performance Status of 0. 5.Adequate bone marrow, liver and renal function 6.Written informed concent
Exclusion criteria
Exclusion criteria: 1.History of treatment except for hepatic resection of RFA 2.History or present of autoimmune disease 3.History or present of inestitial neumonia 4.History of malignancy 5.Renal falure 6.severe heart disease 7.severe hypertension 8.active infection 9.History of treatment using immunotherapy such as immune checkpoint inhibitor, peptide vaccine, biochemical modulator and Lymphocyte stimulation therapy 10.pregnancy or breast feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-year recurrence free survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Reccurence free survival 2-year recurrence free survival rate Overall survival Tumor markers Safety | — |
Countries
Japan
Contacts
Public ContactKazuomi Ueshima
Kindai University Faculty of Medicine Gastroenterology and Hepatology
Outcome results
None listed